Genevant Science Corporation, Unit 155-887 Great Northern Way, Vancouver, British Columbia V5T 4T5, Canada.
ACS Nano. 2024 Apr 16;18(15):10374-10387. doi: 10.1021/acsnano.3c09028. Epub 2024 Apr 3.
The advent of mRNA for nucleic acid (NA) therapeutics has unlocked many diverse areas of research and clinical investigation. However, the shorter intracellular half-life of mRNA compared with other NAs may necessitate more frequent dosing regimens. Because lipid nanoparticles (LNPs) are the principal delivery system used for mRNA, this could lead to tolerability challenges associated with an accumulated lipid burden. This can be addressed by introducing enzymatically cleaved carboxylic esters into the hydrophobic domains of lipid components, notably, the ionizable lipid. However, enzymatic activity can vary significantly with age, disease state, and species, potentially limiting the application in humans. Here we report an alternative approach to ionizable lipid degradability that relies on nonenzymatic hydrolysis, leading to a controlled and highly efficient lipid clearance profile. We identify highly potent examples and demonstrate their exceptional tolerability in multiple preclinical species, including multidosing in nonhuman primates (NHP).
信使 RNA(mRNA)核酸(NA)疗法的出现为许多不同领域的研究和临床探索打开了大门。然而,与其他 NA 相比,mRNA 的细胞内半衰期更短,这可能需要更频繁的给药方案。由于脂质纳米粒(LNP)是用于 mRNA 的主要递送系统,这可能会导致与累积脂质负担相关的耐受性挑战。通过在脂质成分的疏水区(尤其是可离子化脂质)中引入酶切羧酸酯,可以解决这个问题。然而,酶活性会因年龄、疾病状态和物种的不同而有很大差异,这可能限制了在人类中的应用。在这里,我们报告了一种依赖于非酶水解的可离子化脂质降解的替代方法,从而实现了可控且高效的脂质清除。我们鉴定了高活性的实例,并在包括非人灵长类动物(NHP)在内的多个临床前物种中证明了它们的优异耐受性,包括多次给药。